JP2015505245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505245A5 JP2015505245A5 JP2014550413A JP2014550413A JP2015505245A5 JP 2015505245 A5 JP2015505245 A5 JP 2015505245A5 JP 2014550413 A JP2014550413 A JP 2014550413A JP 2014550413 A JP2014550413 A JP 2014550413A JP 2015505245 A5 JP2015505245 A5 JP 2015505245A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- pdgfc
- subject
- rna
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100007816 PDGFC Human genes 0.000 claims description 71
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 71
- -1 LOC731777 Proteins 0.000 claims description 44
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 15
- 102100016014 IFT52 Human genes 0.000 claims description 12
- 101700034131 IFT52 Proteins 0.000 claims description 12
- 239000000090 biomarker Substances 0.000 claims description 9
- 102100012422 RRBP1 Human genes 0.000 claims description 7
- 101700079482 RRBP1 Proteins 0.000 claims description 7
- 102100005591 WSB2 Human genes 0.000 claims description 7
- 101700021207 WSB2 Proteins 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 102100004948 ABCD1 Human genes 0.000 claims description 6
- 101710026064 ACTA2 Proteins 0.000 claims description 6
- 102100018913 ACTA2 Human genes 0.000 claims description 6
- 102100017941 ALDH3B1 Human genes 0.000 claims description 6
- 101710007427 ALDH3B1 Proteins 0.000 claims description 6
- 102100019714 AZIN1 Human genes 0.000 claims description 6
- 101700084615 BTF3 Proteins 0.000 claims description 6
- 102100015491 BTN3A2 Human genes 0.000 claims description 6
- 101710012706 BTN3A2 Proteins 0.000 claims description 6
- 101710012717 BTN3A3 Proteins 0.000 claims description 6
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 6
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 claims description 6
- 102100020192 EPSTI1 Human genes 0.000 claims description 6
- 101710030058 EPSTI1 Proteins 0.000 claims description 6
- 206010015150 Erythema Diseases 0.000 claims description 6
- 102100014605 FBXO30 Human genes 0.000 claims description 6
- 101710027292 FBXO30 Proteins 0.000 claims description 6
- 101710045028 FBXO7 Proteins 0.000 claims description 6
- 102100000186 FBXO7 Human genes 0.000 claims description 6
- 102000013601 Fanconi Anemia Complementation Group D2 Protein Human genes 0.000 claims description 6
- 108010026653 Fanconi Anemia Complementation Group D2 Protein Proteins 0.000 claims description 6
- 201000000142 Fanconi anemia complementation group D2 Diseases 0.000 claims description 6
- 102100004780 GNB4 Human genes 0.000 claims description 6
- 101710037911 GNB4 Proteins 0.000 claims description 6
- 102100020265 HEMGN Human genes 0.000 claims description 6
- 101700015675 HEMGN Proteins 0.000 claims description 6
- 102100005256 HPS1 Human genes 0.000 claims description 6
- 101700086186 HPS1 Proteins 0.000 claims description 6
- 102100014270 IFRD2 Human genes 0.000 claims description 6
- 101700056915 IFRD2 Proteins 0.000 claims description 6
- 102100008236 IMMP2L Human genes 0.000 claims description 6
- 101710008897 IMMP2L Proteins 0.000 claims description 6
- 102100015290 LRSAM1 Human genes 0.000 claims description 6
- 101710005890 LRSAM1 Proteins 0.000 claims description 6
- 102100016478 MACO1 Human genes 0.000 claims description 6
- 101700049850 MACO1 Proteins 0.000 claims description 6
- 101700076085 MYL5 Proteins 0.000 claims description 6
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 6
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 claims description 6
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 claims description 6
- 101710021097 PAPSS1 Proteins 0.000 claims description 6
- 102100018844 PAPSS1 Human genes 0.000 claims description 6
- 102100020472 PLAAT2 Human genes 0.000 claims description 6
- 101710009195 PLAAT2 Proteins 0.000 claims description 6
- 102100000959 RGCC Human genes 0.000 claims description 6
- 101700018446 RGCC Proteins 0.000 claims description 6
- 102100004479 SIGLEC7 Human genes 0.000 claims description 6
- 101710045220 SIGLEC7 Proteins 0.000 claims description 6
- 102100018409 SLC24A4 Human genes 0.000 claims description 6
- 108091006617 SLC24A4 Proteins 0.000 claims description 6
- 102100003711 SLC49A3 Human genes 0.000 claims description 6
- 101710029302 SLC49A3 Proteins 0.000 claims description 6
- 102100014928 SRSF8 Human genes 0.000 claims description 6
- 101700058002 SRSF8 Proteins 0.000 claims description 6
- 102100009541 TMCC1 Human genes 0.000 claims description 6
- 101700085403 TMCC1 Proteins 0.000 claims description 6
- 102100008560 UBB Human genes 0.000 claims description 6
- 101700023322 UBB Proteins 0.000 claims description 6
- 102100018234 XPOT Human genes 0.000 claims description 6
- 101700058470 XPOT Proteins 0.000 claims description 6
- 102100013985 YBEY Human genes 0.000 claims description 6
- 101700040559 YBEY Proteins 0.000 claims description 6
- 108010035632 ornithine decarboxylase antizyme inhibitor Proteins 0.000 claims description 6
- 208000006820 Arthralgia Diseases 0.000 claims description 5
- 102100007819 C1QC Human genes 0.000 claims description 5
- 101700027658 C1QC Proteins 0.000 claims description 5
- 102100003798 CCDC24 Human genes 0.000 claims description 5
- 101710022636 CCDC24 Proteins 0.000 claims description 5
- 102100019348 CEBPA Human genes 0.000 claims description 5
- 101700058775 CEBPA Proteins 0.000 claims description 5
- 206010049047 Chapped lips Diseases 0.000 claims description 5
- 208000006331 Coronary Aneurysm Diseases 0.000 claims description 5
- 102100014126 DAB2 Human genes 0.000 claims description 5
- 101700054205 DAB2 Proteins 0.000 claims description 5
- 208000010201 Exanthema Diseases 0.000 claims description 5
- 102100008643 FHOD1 Human genes 0.000 claims description 5
- 101700034500 FHOD1 Proteins 0.000 claims description 5
- 210000004013 Groin Anatomy 0.000 claims description 5
- 206010024570 Lip swelling Diseases 0.000 claims description 5
- 102100018969 OASL Human genes 0.000 claims description 5
- 101700014794 OASL Proteins 0.000 claims description 5
- 102100010668 OLFM4 Human genes 0.000 claims description 5
- 101700072644 OLFM4 Proteins 0.000 claims description 5
- 102100000015 PGM5 Human genes 0.000 claims description 5
- 101700023297 PGM5 Proteins 0.000 claims description 5
- 206010037660 Pyrexia Diseases 0.000 claims description 5
- 206010037844 Rash Diseases 0.000 claims description 5
- 102100002156 TOR4A Human genes 0.000 claims description 5
- 101700076071 TOR4A Proteins 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 231100000321 erythema Toxicity 0.000 claims description 5
- 201000005884 exanthem Diseases 0.000 claims description 5
- 201000003265 lymphadenitis Diseases 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102100003475 CMTM4 Human genes 0.000 claims description 4
- 101710002896 CMTM4 Proteins 0.000 claims description 4
- 210000004904 fingernail beds Anatomy 0.000 claims description 4
- 201000005111 ocular hyperemia Diseases 0.000 claims description 4
- 102100002679 H3C13 Human genes 0.000 claims description 3
- 101710007249 H3C15 Proteins 0.000 claims description 3
- 101710015837 LGALS9 Proteins 0.000 claims description 3
- 102100004651 LGALS9 Human genes 0.000 claims description 3
- 101710038793 SERPINB2 Proteins 0.000 claims description 3
- 102100019904 SERPINB2 Human genes 0.000 claims description 3
- 210000002966 Serum Anatomy 0.000 claims description 3
- 210000003491 Skin Anatomy 0.000 claims description 3
- 102100002574 WLS Human genes 0.000 claims description 3
- 101700074519 WLS Proteins 0.000 claims description 3
- 102100013575 ZNF138 Human genes 0.000 claims description 3
- 101710002445 ZNF138 Proteins 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 208000006740 Aseptic Meningitis Diseases 0.000 claims description 2
- 206010027201 Meningitis aseptic Diseases 0.000 claims description 2
- 102100015316 PYROXD1 Human genes 0.000 claims description 2
- 108060001608 PYROXD1 Proteins 0.000 claims description 2
- 206010040844 Skin exfoliation Diseases 0.000 claims description 2
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 230000002522 swelling Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100015076 ETFA Human genes 0.000 claims 3
- 101700008114 ETFA Proteins 0.000 claims 3
- 101700026565 GA2 Proteins 0.000 claims 3
- 101700067906 GPA2 Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000007313 Kawasaki disease Diseases 0.000 claims 1
- 101700010171 LA1 Proteins 0.000 claims 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 claims 1
- 101700052054 PS1 Proteins 0.000 claims 1
- 102100008812 PSEN1 Human genes 0.000 claims 1
- 101710033350 PSEN1 Proteins 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000000875 corresponding Effects 0.000 description 5
- 206010023232 Joint swelling Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 201000009906 meningitis Diseases 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 1
- 101700019411 PAPSS Proteins 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161581199P | 2011-12-29 | 2011-12-29 | |
| US61/581,199 | 2011-12-29 | ||
| PCT/US2012/071360 WO2013101758A1 (en) | 2011-12-29 | 2012-12-21 | Biomarkers for kawasaki disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505245A JP2015505245A (ja) | 2015-02-19 |
| JP2015505245A5 true JP2015505245A5 (hr) | 2016-02-12 |
Family
ID=47459205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550413A Pending JP2015505245A (ja) | 2011-12-29 | 2012-12-21 | 川崎病のためのバイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140348818A1 (hr) |
| EP (1) | EP2798081A1 (hr) |
| JP (1) | JP2015505245A (hr) |
| KR (1) | KR20140108718A (hr) |
| CN (1) | CN104160039B (hr) |
| CA (1) | CA2862270A1 (hr) |
| WO (1) | WO2013101758A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015168602A2 (en) * | 2014-05-02 | 2015-11-05 | Momenta Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of kawasaki disease |
| CN104450901B (zh) * | 2014-11-27 | 2016-09-21 | 广州赛哲生物科技股份有限公司 | 快速诊断川崎病的核酸标记物及其试剂盒 |
| JP6153239B2 (ja) * | 2015-02-10 | 2017-06-28 | 公立大学法人横浜市立大学 | 川崎病の検査方法およびキット |
| CN105112552B (zh) * | 2015-09-28 | 2018-02-27 | 北京泱深生物信息技术有限公司 | Ift52基因在骨质疏松症诊断中的应用 |
| US11448648B2 (en) | 2016-11-11 | 2022-09-20 | Ascendant Diagnostics, LLC | Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and Kawasaki disease |
| CN106701962B (zh) * | 2016-12-28 | 2020-07-28 | 广州赛哲生物科技股份有限公司 | 用于川崎病检测的引物组、探针及试剂盒 |
| CN106636413B (zh) * | 2016-12-28 | 2019-07-16 | 常州市第二人民医院 | 一种用于诊断哮喘的分子标志物 |
| CN110824173B (zh) * | 2019-11-27 | 2022-09-02 | 中国人民解放军陆军军医大学第一附属医院 | 促血管生成因子pdgfc在作为诊断和治疗肝肺综合征的标志物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US5286623A (en) * | 1991-11-26 | 1994-02-15 | National Jewish Center For Immunology And Respiratory Medicine | Method for screening for Kawasaki disease |
| US5279721A (en) | 1993-04-22 | 1994-01-18 | Peter Schmid | Apparatus and method for an automated electrophoresis system |
| DE602005027673D1 (de) * | 2004-03-05 | 2011-06-09 | Vegenics Pty Ltd | Materialien und verfahren für wachstumsfaktorbindende konstrukte |
| JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| WO2010025393A2 (en) | 2008-08-28 | 2010-03-04 | The Regents Of The University Of California | Protein biomarkers and methods for diagnosing kawasaki disease |
| CN102482715A (zh) * | 2009-07-13 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | 用于癌症治疗的诊断方法和组合物 |
-
2012
- 2012-12-21 WO PCT/US2012/071360 patent/WO2013101758A1/en active Application Filing
- 2012-12-21 CA CA2862270A patent/CA2862270A1/en not_active Abandoned
- 2012-12-21 EP EP12808661.8A patent/EP2798081A1/en not_active Withdrawn
- 2012-12-21 JP JP2014550413A patent/JP2015505245A/ja active Pending
- 2012-12-21 US US14/362,857 patent/US20140348818A1/en not_active Abandoned
- 2012-12-21 CN CN201280070975.0A patent/CN104160039B/zh active Active
- 2012-12-21 KR KR1020147021229A patent/KR20140108718A/ko not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505245A5 (hr) | ||
| Lee et al. | SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice | |
| Farber et al. | Five-year outcomes of patients enrolled in the REVEAL Registry | |
| Kimball et al. | HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study | |
| Alnasser et al. | Late consequences of acute coronary syndromes: global registry of acute coronary events (GRACE) follow-up | |
| Hong et al. | Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation–related mild ischemic stroke: a randomized clinical trial | |
| Goldberger et al. | Risk stratification for sudden cardiac death: a plan for the future | |
| Bible et al. | Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study | |
| Greaves et al. | Myocardial contrast echocardiography is superior to other known modalities for assessing myocardial reperfusion after acute myocardial infarction | |
| Curtis et al. | Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis | |
| Kovacs et al. | Characterization of patients with borderline pulmonary arterial pressure | |
| Durheim et al. | Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group | |
| Chou et al. | Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). | |
| JP2017512507A (ja) | 心不全のリスクを決定するための方法およびシステム | |
| Alexander et al. | A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer | |
| Johnson et al. | Clinical features and outcome in 25 dogs with respiratory‐associated pulmonary hypertension treated with sildenafil | |
| Hrynkiewicz-Szymanska et al. | Association of the CHADS 2 and CHA 2 DS 2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients | |
| Kleiner Shochat et al. | Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE‐HF extended trial | |
| Johnson et al. | Pulmonary hypertension: a contemporary review | |
| Calandra-Buonaura et al. | Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson’s disease | |
| Hendriks et al. | The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension | |
| Chang et al. | Increased risk of first-ever stroke in younger patients with atrial fibrillation not recommended for antithrombotic therapy by current guidelines: a population-based study in an East Asian cohort of 22 million people | |
| Eder et al. | Responses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials | |
| Lally et al. | Personalised approaches to pharmacotherapy for schizophrenia | |
| JP2020531539A (ja) | カナキヌマブの使用 |